Strategic partnerships Target collaborations with veterinary pharmaceutical distributors and pet healthcare platforms to leverage Anivive's computational and clinical capabilities in accelerating therapeutic development, building on existing Dechra partnerships and their out-licensing activities.

Pipeline expansion Position to upsell ongoing Valley Fever vaccine initiatives and related antifungal programs to biomedical research labs, veterinary clinics, and pet owners, highlighting potential cross-domain applications from animal to human health opportunities.

Investors & funds Leverage recent $20M investments and overall funding to pursue strategic co-development deals, licensing conversations, and milestone-driven collaborations with mid-size biotechs and veterinary players seeking innovation in pet therapeutics.

Public engagement Capitalize on visibility from World Vaccine Congress and NIH-funding discussions by arranging executive briefings, analyst meetings, and customer-focused demonstrations of the live-attenuated vaccine platform and its translational potential.

Tech-enabled outreach Utilize Anivive’s tech stack and digital presence to run targeted marketing and partner outreach at scale, emphasizing software-driven discovery, clinical research acceleration, and rapid deployment capabilities to differentiate from traditional pet pharma incumbents.